Thilo Schroeder - 05 Dec 2024 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Director
Signature
/s/ Darren DeStefano, Attorney-in-Fact
Issuer symbol
RVMD
Transactions as of
05 Dec 2024
Net transactions value
+$59,999,962
Form type
4
Filing time
09 Dec 2024, 16:15:16 UTC
Previous filing
14 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Purchase $24,999,988 +543,478 +35% $46.00 2,096,612 05 Dec 2024 By Nextech Crossover I SCSP F1
transaction RVMD Common Stock Purchase $34,999,974 +760,869 $46.00 760,869 05 Dec 2024 By Nextech VIII SCSP F2
holding RVMD Common Stock 3,590,313 05 Dec 2024 By Nextech V Oncology S.C.S., SICAV-SIF F3
holding RVMD Common Stock 1,153,293 05 Dec 2024 By Nextech VI Oncology SCSp F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F2 Nextech Invest AG is the investment advisor of Nextech VIII SCSP ("Nextech VIII"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VIII. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3 Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4 Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The Reporting Person is a managing member of Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.